Mousavizadeh K, Rahimian R, Fakhfouri G, Aslani F S, Ghafourifar P
Iran University of Medical Sciences, Tehran.
Eur J Clin Invest. 2009 May;39(5):375-83. doi: 10.1111/j.1365-2362.2009.02102.x.
There is a pressing need for research that will lead to the development of new therapeutic approaches for treating inflammatory bowel disease (IBD). The aim of this study was to investigate the effects of tropisetron, a 5-Hydroxytryptamine (5-HT)-3 receptor antagonist with anti-inflammatory properties in a model of experimental colitis in rat.
Acetic acid model of colitis in rats was used. Colitis was induced by intracolonal instillation of 4% (v/v) acetic acid. One hour after induction of colitis, intraperitoneal (IP) or intrarectal (IR) tropisetron (2 mg kg(-1), either route) or dexamethasone (1 mg kg(-1), either route) was administered. The severity of colitis was assessed 24 h later using macroscopic and microscopic changes of damaged colon, measurement of inflammatory cytokines interleukin-1beta, interleukin-6 and tumour necrosis factor-alpha levels and oxidative stress markers myeloperoxidase (MPO) and malondialdehyde (MDA) in colonic tissues.
Tropisetron decreased colonic macroscopic and microscopic damage scores. This was associated with significant reduction in both neutrophil infiltration indicated by decreased colonic MPO activity and lipid peroxidation measured by MDA content, as well as a decreased colonic inflammatory cytokines. IR tropisetron decreased colonic damage that was associated with decreased neutrophil infiltration, lipid peroxidation and colonic inflammatory cytokines. Beneficial effects of tropisetron were lower than those of dexamethasone. No significant differences were observed between IP and IR administration with the exception of MDA level more diminished by IP tropisetron and dexamethasone.
Tropisetron exert beneficial effects in experimental rat colitis and therefore might be useful in the treatment of IBD.
迫切需要开展相关研究,以开发治疗炎症性肠病(IBD)的新治疗方法。本研究的目的是在大鼠实验性结肠炎模型中,研究具有抗炎特性的5-羟色胺(5-HT)-3受体拮抗剂托烷司琼的作用。
采用大鼠乙酸结肠炎模型。通过向结肠内注入4%(v/v)乙酸诱导结肠炎。在诱导结肠炎1小时后,腹腔内(IP)或直肠内(IR)给予托烷司琼(2 mg kg⁻¹,两种途径均可)或地塞米松(1 mg kg⁻¹,两种途径均可)。24小时后,通过受损结肠的宏观和微观变化、炎症细胞因子白细胞介素-1β、白细胞介素-6和肿瘤坏死因子-α水平的测定以及结肠组织中氧化应激标志物髓过氧化物酶(MPO)和丙二醛(MDA)的测量,评估结肠炎的严重程度。
托烷司琼降低了结肠的宏观和微观损伤评分。这与结肠MPO活性降低所表明的中性粒细胞浸润显著减少以及MDA含量所测量的脂质过氧化减少以及结肠炎症细胞因子减少有关。IR托烷司琼降低了结肠损伤,这与中性粒细胞浸润、脂质过氧化和结肠炎症细胞因子减少有关。托烷司琼的有益作用低于地塞米松。除IP托烷司琼和地塞米松使MDA水平降低更多外,IP和IR给药之间未观察到显著差异。
托烷司琼在实验性大鼠结肠炎中发挥有益作用,因此可能对IBD的治疗有用。